225 related articles for article (PubMed ID: 1773046)
1. MHC gene control of the natural killer system at the level of the target and the host.
Kärre K
Semin Cancer Biol; 1991 Oct; 2(5):295-309. PubMed ID: 1773046
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of human and mouse natural killer tumor recognition using retroviral antisense in primary natural killer cells: involvement with MHC class I killer cell inhibitory receptors.
Ortaldo JR; Mason AT; Mason LH; Winkler-Pickett RT; Gosselin P; Anderson SK
J Immunol; 1997 Feb; 158(3):1262-7. PubMed ID: 9013968
[TBL] [Abstract][Full Text] [Related]
3. H-2Dp transgene alters natural killer cell specificity at the target and effector cell levels. Comparison with an H-2Dd transgene.
Sentman CL; Olsson-Alheim MY; Lendahl U; Kärre K
J Immunol; 1996 Apr; 156(7):2423-9. PubMed ID: 8786300
[TBL] [Abstract][Full Text] [Related]
4. Missing self recognition by natural killer cells in MHC class I transgenic mice. A 'receptor calibration' model for how effector cells adapt to self.
Sentman CL; Olsson MY; Kärre K
Semin Immunol; 1995 Apr; 7(2):109-19. PubMed ID: 7579193
[TBL] [Abstract][Full Text] [Related]
5. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
6. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
7. Human NK cell education by inhibitory receptors for MHC class I.
Anfossi N; André P; Guia S; Falk CS; Roetynck S; Stewart CA; Breso V; Frassati C; Reviron D; Middleton D; Romagné F; Ugolini S; Vivier E
Immunity; 2006 Aug; 25(2):331-42. PubMed ID: 16901727
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
Kijima M; Saio M; Oyang GF; Suwa T; Miyauchi R; Kojima Y; Imai H; Nakagawa J; Nonaka K; Umemura N; Nishimura T; Takami T
Int J Oncol; 2005 Mar; 26(3):679-84. PubMed ID: 15703823
[TBL] [Abstract][Full Text] [Related]
9. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
10. In vivo generation, enhancement and recruitment of host cellular immune responses against tumor: influence of MHC antigen expression on clones of tumor cell variants.
Fernández-Cruz E; Pérez M; Zabay JM; Garrido F
Prog Clin Biol Res; 1987; 244():115-25. PubMed ID: 2958867
[No Abstract] [Full Text] [Related]
11. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL.
Bakker AB; Phillips JH; Figdor CG; Lanier LL
J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119
[TBL] [Abstract][Full Text] [Related]
12. H-2 allele-specific protection from NK cell lysis in vitro for lymphoblasts but not tumor targets. Protection mediated by alpha 1/alpha 2 domains.
Sentman CL; Olsson MY; Salcedo M; Höglund P; Lendahl U; Käre K
J Immunol; 1994 Dec; 153(12):5482-90. PubMed ID: 7989750
[TBL] [Abstract][Full Text] [Related]
13. Role of major histocompatibility complex class I alpha 1/alpha 2 domain polymorphism and in vivo expression pattern in tumor resistance: studies with transgenic mice and lymphoma cell transfectants.
Höglund P; Waldenström M; Kärre K
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):175-81. PubMed ID: 8297899
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
Melief CJ; Kast WM
Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
[TBL] [Abstract][Full Text] [Related]
15. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.
Kärre K; Ljunggren HG; Piontek G; Kiessling R
Nature; 1986 Feb 20-26; 319(6055):675-8. PubMed ID: 3951539
[TBL] [Abstract][Full Text] [Related]
16. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
17. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
18. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
19. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
20. Host MHC class I molecules modulate in vivo expression of a NK cell receptor.
Karlhofer FM; Hunziker R; Reichlin A; Margulies DH; Yokoyama WM
J Immunol; 1994 Sep; 153(6):2407-16. PubMed ID: 8077656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
